 "Strides Arcolab, Shasun Pharma gain on Bombay High Court nod for merger")
Shares of Strides Arcolab and Shasun Pharmaceuticals rallied up to 7% on the Bombay Stock Exchange (BSE) after the Bombay High Court approved the merger of these companies.
“The Hon’ble High Court of Bombay has on August 28, 2015 orally pronounced an Order, approving the scheme of amalgamation involving merger of Shasun Pharmaceuticals with the company, Strides Arcolab Limited,” Strides Arcolab said in a BSE filing.
The certified true copy of the said Order is awaited, it added.
The scheme of amalgamation shall be effective post receipt of approval of Foreign Investment Promotion Board (FIPB) and on filing of a copy of the Order with Registrar of Companies, Bombay.
Shasun shareholders would receive 5 equity shares of Strides for every 16 shares held by them in Shasun.
Combined entity to be amongst the top 15 listed Indian pharmaceutical companies by revenue with a turnover in excess of Rs 2,500 crore.
Among the individual stocks, Shasun Pharmaceuticals rallied 7% to Rs 374, while Strides Arcolab gained 5% to Rs 1,220 on the BSE.
“The Hon’ble High Court of Bombay has on August 28, 2015 orally pronounced an Order, approving the scheme of amalgamation involving merger of Shasun Pharmaceuticals with the company, Strides Arcolab Limited,” Strides Arcolab said in a BSE filing.
The certified true copy of the said Order is awaited, it added.
The scheme of amalgamation shall be effective post receipt of approval of Foreign Investment Promotion Board (FIPB) and on filing of a copy of the Order with Registrar of Companies, Bombay.
Shasun shareholders would receive 5 equity shares of Strides for every 16 shares held by them in Shasun.
Combined entity to be amongst the top 15 listed Indian pharmaceutical companies by revenue with a turnover in excess of Rs 2,500 crore.
Among the individual stocks, Shasun Pharmaceuticals rallied 7% to Rs 374, while Strides Arcolab gained 5% to Rs 1,220 on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%